Clinical Trials

122 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

GastrointestinalHead & NeckSarcomaThoracic

122 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT06008054 2025-09-26

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Phase 2 Recruiting

376 enrolled

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06280495 2025-05-30

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2/3 Recruiting

156 enrolled

Colorectal Neoplasms

NCT06794086 2025-05-13

SPARKLE-L

Phase 3 Recruiting

24 enrolled

Colorectal Neoplasms

NCT04171141 2025-01-16

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

79 enrolled 42 charts

Digestive System Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

48 enrolled

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06120127 2023-11-07

IMPROVE

Phase 2 Unknown

80 enrolled

Colorectal Neoplasms

NCT05684211 2023-02-01

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Phase 2 Unknown

84 enrolled

Colorectal Neoplasms

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

BreastGastrointestinalGenitourinaryThoracic

298 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04833387 2023-01-11

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

Phase 2 Active not recruiting

30 enrolled

Colorectal Neoplasms

NCT03668431 2022-06-27

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Phase 2 Unknown

25 enrolled

Colorectal Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

BreastGastrointestinalThoracic

283 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT02947165 2022-01-31

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

BreastGastrointestinalGenitourinaryThoracic

120 enrolled

Breast Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04001101 2021-11-30

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Phase 2 Withdrawn

Turcot syndrome, Neoplasm Metastasis, Colorectal Neoplasms

NCT03176264 2021-10-12

PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

1 enrolled

Colorectal Neoplasms

NCT03081494 2020-12-11

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

10 enrolled